LianBio Q3 net loss narrows to $13.1M; completed $334.5M IPO

LianBio

Net loss of $13.1M ($0.63 per share) narrowed from $120.2M ($11.71) in Q3 2020.
R&D expenses fell to $4.7M from $116.9M; G&A increased to $8.9M from $2.1M.
Completed IPO raising $334.5M gross ($311.1M net); cash position sufficient through 2023.
Initiated PK study of mavacamten and Phase 2a trial of infigratinib in China.
Appointed Jesse Wu and Susan Silbermann to board; new chief scientific advisor and China GM.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.